Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Biotech
J&J axes eye disease gene therapy after key phase 2b readout
Johnson & Johnson stopped development of the eye disease gene therapy after reviewing data from one of its key readouts for 2026.
Nick Paul Taylor
Jul 15, 2026 10:26am
Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet
Jun 24, 2026 7:00am
Discreet biotech Osanni Bio starts making noise with $190M
Jun 23, 2026 2:28pm
Ocugen eye disease gene therapy nabs ph. 2 win
Mar 24, 2026 10:40am
Innovent eyes China approval after matching Eylea in phase 3
Mar 24, 2026 6:00am
Kalaris pauses eye drug trial to resolve ocular inflammation
Mar 11, 2026 6:30am
